EBS News and Press, Emergent Biosolutions Inc. From 04/16/19

Preliminary data from a Phase 2 clinical trial evaluating Emergent BioSolutions' (NYSE: EBS ) Fast Track-tagged CHIKV-VLP, its chikungunya virus-like particle vaccine candidate, showed a positive effect. Seroconversion occurred in 74 - 98% of participants by day 7 after a single dose and ...

GAITHERSBURG, Md., April 16, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV-VLP) vacc...

Emergent BioSolutions (NYSE: EBS ) initiates a Phase 3 trial enrolling 3,850 subjects to evaluate the lot consistency, immunogenicity, and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) in healthy adults. More news on: Emergent BioSolutions Inc., Healthcare stocks new...

GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) following a two-dose schedule...

The U.S. State Department has awarded an indefinite-delivery, indefinite-quantity contract to Emergent BioSolutions (NYSE: EBS ) to establish a durable supply chain for medical countermeasures aimed at chemical warfare agents. More news on: Emergent Biosolutions, Inc., Healthcare stocks ...

GAITHERSBURG, Md., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the U.S. Department of State to establish a long-term, reliable, and stable supply chain for medica...

Emergent Biosolutions ( EBS ) is a midcap biopharma with a focus on PHTs or public health threats, whether accidental, naturally occurring or intentional. This includes targeting anthrax, for which the company has an approved product, Zika virus and other pipeline product candidates. The follo...

Emergent BioSolutions Inc. (EBS) Q4 2018 Earnings Conference Call February 21, 2019 5:00 PM ET Company Participants Bob Burrows – Vice President-Investor Relations Dan Abdun-Nabi – Chief Executive Officer Bob Kramer – President and Chief Operating Officer R...

Emergent BioSolutions (NYSE: EBS ): Q4 Non-GAAP EPS of $0.75 beats by $0.09 ; GAAP EPS of -$0.07 misses by $0.11 . More news on: Emergent BioSolutions Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

GAITHERSBURG, Md., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2018. FINANCIAL HIGHLIGHTS 2018 FINANCIAL PERFORMANCE (I) Quarter Ended December 31, 2018 (Unaudited) Revenu...